Biomedical subjects

Moses Sing Sum Chow

Publications and source records attributed to Moses Sing Sum Chow.

4 recordsLinked to original sources

PubMed2005

Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use.

Danshen, the dried root of Salvia miltiorrhiza, has been widely used in China and, to a lesser extent, in Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases. In China, the specific clinical use is angina pectoris, hyperlipidemia, and acute ischemic stroke. The current review covers its traditional uses, chemical constituents, pharmacological activities, pharmacokinetics, clinical applications, and potential herb-drug interactions based on information obtained in both the English and Chinese literature. Although numerous clinical trials have demonstrated that certain Danshen products in China are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality. Therefore, large randomized clinical trials and further scientific research to determine its mechanism of actions will be necessary to ensure the safety, effectiveness, and better understanding of its action.

Abietanes↗

PubMed2004

Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong.

A prospective controlled study on the benefits of pharmacists' individualized counseling on drug compliance, cholesterol concentration reduction, attainment of National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) low-density lipoprotein cholesterol (LDL-C) goals, and patient satisfaction was carried out in a private community hospital in Hong Kong. All patients who were newly prescribed with lipid-lowering drugs for primary prevention were included. The patients in the individualized counseling group received "intense" counseling and follow-up of cholesterol concentration by a pharmacist for 3 months. The control group received routine counseling. Fifty patients completed the study (26 in the individualized group, 24 in the control group). Compliance was assessed, and those patients who achieved 75% compliance were defined as compliers. In the individualized group, 76.9% were compliers compared with 41.7% in the control group (p < 0.01). The individualized group achieved 28.3%, 27.7%, and 26.1% reduction in total cholesterol, LDL-C, and triglycerides, respectively, compared with 15.3%, 16.3%, and 10.6% in the control group (p < 0.05 for all). Also in the individualized group, 80.8% achieved the ATP III LDL-C goals compared to 58.3% in the control group (p < 0.05). Of patients in the individualized group, 85% felt that the pharmacist counseling service could improve their disease management. The study demonstrated that pharmacists' individualized counseling, together with the assessment of cholesterol concentrations, had positive impacts on the management of hyperlipidemia, including improved drug compliance, better treatment endpoints, and patient satisfaction.

Cholesterol↗

PubMed2003

Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study.

BACKGROUND: Stevioside, a natural glycoside isolated from the plant Stevia rebaudiana Bertoni, has been used as a commercial sweetening agent in Japan and Brazil for >20 years. Previous animal and human studies have indicated that stevioside has an antihypertensive effect. OBJECTIVES: This study was undertaken to investigate the long-term (2-year) efficacy and tolerability of stevioside in patients with mild essential hypertension. Secondary objectives were to determine the effects of stevioside on left ventricular mass index (LVMI) and quality of life (QOL). METHODS: This was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese men and women aged between 20 and 75 years with mild essential hypertension (systolic blood pressure [SBP] 140-159 mm Hg and diastolic blood pressure [DBP] 90-99 mm Hg). Patients took capsules containing 500 mg stevioside powder or placebo 3 times daily for 2 years. Blood pressure was measured at monthly clinic visits; patients were also encouraged to monitor blood pressure at home using an automated device. LVMI was determined by 2-dimensional echocardiography at baseline and after 1 and 2 years of treatment. QOL was assessed using the Medical Outcomes Study 36-Item Short-Form Health Survey. Electrocardiographic, laboratory, and QOL parameters were assessed at the beginning of treatment, and at 6 months, 1 year, and 2 years. RESULTS: One hundred seventy-four patients (87 men, 87 women) were enrolled in the study, and 168 completed it: 82 (42 men, 40 women; mean [SD] age, 52 [7] years) in the stevioside group and 86 (44 women, 42 men; mean age, 53 [7] years) in the placebo group. After 2 years, the stevioside group had significant decreases in mean (SD) SBP and DBP compared with baseline (SBP, from 150 [7.3] to 140 [6.8] mm Hg; DBP, from 95 [4.2] to 89 [3.2] mm Hg; P < 0.05) and compared with placebo (P < 0.05). Based on patients' records of self-monitored blood pressure, these effects were noted beginning approximately 1 week after the start of treatment and persisted throughout the study. There were no significant changes in body mass index or blood biochemistry, and the results of laboratory tests were similar in the 2 groups throughout the study. No significant difference in the incidence of adverse effects was noted between groups, and QOL scores were significantly improved overall with stevioside compared with placebo (P < 0.001). Neither group had a significant change in mean LVMI. However, after 2 years, 6 of 52 patients (11.5%) in the stevioside group had left ventricular hypertrophy (LVH), compared with 17 of 50 patients (34.0%) in the placebo group (P < 0.001). Of those who did not have LVH at baseline, 3 of 46 patients (6.5%) in the stevioside group had developed LVH after 2 years, compared with 9 of 37 patients (24.3%) in the placebo group (P < 0.001). CONCLUSIONS: In this 2-year study in Chinese patients with mild hypertension, oral stevioside significantly decreased SBP and DBP compared with placebo. QOL was improved, and no significant adverse effects were noted.

Administration, Oral↗

PubMed2002

Hawthorn.

A review with 54 references covers all aspects of hawthorn, the genus Crataegus, including its traditional uses, chemical constituents, pharmacological activities, and clinical effects. Although the effectiveness of hawthorn on the treatment of cardiovascular diseases has received extensive attention worldwide, further scientific research on various areas such as pharmacokinetics, mechanism of actions will be necessary to ensure its safe and effective usage.

Crataegus↗